Results 91 to 100 of about 481,131 (293)

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

Tumor Suppressor Genes [PDF]

, 2012
Functional evidence obtained from somatic cell fusion studies indicated that a group of genes from normal cells might replace or correct a defective function of cancer cells. Tumorigenesis that could be initiated by two mutations was established by the analysis of hereditary retinoblastoma, which led to the eventual cloning of RB1 gene.
openaire   +3 more sources

EVALUATING THE THERAPEUTIC EFFICACY OF RESTORING WILD-TYPE P53 ACTIVITY IN P53-MUTANT TUMORS [PDF]

, 2017
The p53 transcription factor is the most frequently altered in human cancers usually via missense mutations that undermine its transcriptional activity. Clinically, TP53 mutations have been shown to be remarkably predictive of refractoriness to treatment,
Larsson, Connie A
core   +1 more source

CONTRASTING EFFECTS OF AN MDM2 FUNCTIONAL POLYMORPHISM ON TUMOR PHENOTYPES [PDF]

, 2017
Cancer predisposition by the cooperation of genetic variants, such as single nucleotide polymorphisms (SNPs), may be of much greater significance to public health than previously appreciated.
Ortiz, Guadalupe J, IV
core   +2 more sources

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23 [PDF]

, 2008
Background: Recurrent loss of part of the long arm of chromosome 11 is a well established hallmark of a subtype of aggressive neuroblastomas. Despite intensive mapping efforts to localize the culprit 11q tumour suppressor gene, this search has been ...
Evi Michels, Jasmien Hoebeeck, Katleen De Preter, Alexander Schramm, Bénédicte Brichard, Anne De Paepe, Angelika Eggert, Geneviève Laureys, Jo Vandesompele, Frank Speleman, WA Weiss, YP Mosse, D Trochet, V van Limpt, EF Attiyeh, J Vandesompele, C Guo, D Plantaz, J Vandesompele, J Vandesompele, CP Koiffmann, Y Mosse, SA Bader, K De Preter, JM Maris, E Michels, GM Brodeur, B Menten, B Berwanger, K De Preter, L McArdle, A Oberthuer, M Ohira, A Schramm, Q Wang, F Pattyn, F Pattyn, J Vandesompele, T Aranyi, GE Tusnady, F Pattyn, CJ Breen, ME Luttikhuis, S Griffiths-Jones, S Griffiths-Jones, R Spitz, L Gangwani, B Doran, GC Owens, AK Perl, J Roesler, P Fogar, H Sasaki, RA Blaheta, T Biederer, M Kuramochi, H Fukuhara, T Ito, Y Murakami, RD Steenbergen, EF Attiyeh, H Gomyo, M Alaminos, B Banelli, M Yageta, A Krause   +65 more
core   +2 more sources

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

Epigenetic upregulation of lncRNAs at 13q14.3 in leukemia is linked to the In Cis downregulation of a gene cluster that targets NF-kB.

PLoS Genetics, 2013
Non-coding RNAs are much more common than previously thought. However, for the vast majority of non-coding RNAs, the cellular function remains enigmatic.
Angela Garding, Nupur Bhattacharya, Rainer Claus, Melanie Ruppel, Cordula Tschuch, Katharina Filarsky, Irina Idler, Manuela Zucknick, Maïwen Caudron-Herger, Christopher Oakes, Verena Fleig, Ioanna Keklikoglou, Danilo Allegra, Leticia Serra, Sudhir Thakurela, Vijay Tiwari, Dieter Weichenhan, Axel Benner, Bernhard Radlwimmer, Hanswalter Zentgraf, Stefan Wiemann, Karsten Rippe, Christoph Plass, Hartmut Döhner, Peter Lichter, Stephan Stilgenbauer, Daniel Mertens   +26 more
doaj   +1 more source

MTSS1 is a critical epigenetically regulated tumor suppressor in CML [PDF]

, 2015
Chronic myeloid leukemia (CML) is driven by malignant stem cells that can persist despite therapy. We have identified Metastasis suppressor 1 (Mtss1/MIM) to be downregulated in hematopoietic stem and progenitor cells from leukemic transgenic SCLtTA/Bcr ...
Braunschweig, T., Brümmendorf, T. H., Chatain, N., Copland, M., Costa, I. G., Gusmao, E. G., Haenzelmann, S., Hamilton, A., Helgason, G.V., Herrmann, O., Holyoake, T. L., Kintsler, S., Koschmieder, S., Li, S., Merle Reher, M., Müller-Tidow, C., Schemionek, M., Schubert, C., Schwab, A.   +18 more
core   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source